Moleculin Announces Full Exercise of Over-Allotment Option
Increases Gross Proceeds to Approximately $78 MillionHOUSTON, Feb. 10, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors...
Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases
HOUSTON, Feb. 8, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań...
Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering
HOUSTON, Feb. 3, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an...
Moleculin Announces Proposed Underwritten Public Offering
HOUSTON, Feb. 2, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it intends to offer...
Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
Annamycin shown to reach "sanctuary sites" of cancerHOUSTON, Feb. 2, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and...
Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial
Annamycin being used to target soft tissue sarcoma lung metastasesHOUSTON, Feb. 1, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant...
Moleculin Announces Reverse Stock Split
HOUSTON, Jan. 29, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it filed a certificate...
Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference
HOUSTON, Jan. 7, 2021 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management...
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
HOUSTON, Dec. 29, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug...
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
HOUSTON, Dec. 17, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug...